Figure 3
From: Drug screening of cancer cell lines and human primary tumors using droplet microfluidics
Four drugs, namely Bortezomib (BZ), Epirubicin (EP), Cisplatin (Cis), and Vorinostat (VR) were used to screen Jurkat cells (a–c) and MDA-MB-231 cells (d–f), as models for suspended and adherent cancer cells respectively, on three drug screening platforms using 96-well plate, 384-well plate and our chip assay. A horizontal dashed line was drawn at 50% cell viability for comparison of IC50 between different screening methods. All graphs were plotted by cell viability (y-axis) against the log of final drug concentration (x-axis); error bars denoted standard deviation of mean cell viability obtained from all replicates in parallel experiments, except for the chip assay of Cisplatin-treated MDA-MB-231 cells (f) where error bars denoted standard deviation of mean cell viability obtained from all droplets of two independent experiments.
